Precision Medicine for Cancer Patients: Lessons Learned and the Path Forward
Open Access
- 20 August 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 105 (17), 1262-1263
- https://doi.org/10.1093/jnci/djt219
Abstract
An explosion in our knowledge of cancer biology has occurred in the decade since the elucidation of the human genome. The potential for translation of this genomic information to the therapeutic management of patients has generated great excitement, although, despite some stellar successes, progress has been slower than expected. However, the concept of personalized or “precision” medicine that integrates genomic knowledge (such as molecular analysis of the patient’s tumor) and other laboratory research with input from health records, along with social and environmental data, for the selection of the optimal therapy for the individual patient remains attractive. Striking examples of success with this approach are the use of BCR-ABL mutations to predict clinical responses to imatinib in chronic myelogenous leukemia and EGFR mutations to predict clinical response to EGFR tyrosine kinase inhibitors in non–small cell lung cancer. These approaches use “enrollment biomarkers” to identify mutant targets to attack with specific therapies. An example of a newly recognized potential enrollment marker is expression of the SLFN11 gene for prediction of sensitivity to topoisomerase inhibitors ( 1 ). Another approach is to use tumor mRNA expression patterns, “molecular signatures,” for response prediction for the selection of conventional cytotoxic therapies. Enrollment biomarker approaches are mechanistically based in that they are directly related to the targeted pathway and thus directly connect the therapy to the tumor’s “oncogene addiction.” Tumor mRNA phenotypes, however, have not been shown to directly relate to the targeted tumor pathway(s) or addiction in most cases. Thus, such approaches are less specific and often rely on gene panels whose mechanistic roles and relevance are not apparent. All such approaches may be facilitated by preclinical models (e.g., tumor cell lines, xenografts, and genetically engineered mouse models of cancer) for which both molecular analyses and therapy response phenotypes can be determined independent of the patient and which can lead to the development of molecular signatures predictive of response to specific therapies. This latter approach permits the widespread, unbiased testing of new therapies and their correlation with molecular markers. Such preclinical models also allow for totally independent testing by multiple investigators of proposed therapies and their molecular correlations and for systematic genetic (e.g., small interfering RNA or short hairpinRNA) and chemical library-wide searches for “tumor acquired vulnerabilities” (synthetic lethalities) to identify previously unknown cancer therapies that have specificity for tumor over normal tissues and also specificities for subtypes within tumors of the same primary type. These approaches are being used by programs such as the National Cancer Institute’s (NCI’s) Cancer Target Discovery and Development (CTD) Network ( 2 ) as well as many pharmaceutical and biotechnology companies.Keywords
This publication has 11 references indexed in Scilit:
- Independent Validation of a Model Using Cell Line Chemosensitivity to Predict Response to TherapyJNCI Journal of the National Cancer Institute, 2013
- The Clinical Relevance of Cancer Cell LinesJNCI Journal of the National Cancer Institute, 2013
- Biomarker Tests Need Closer Scrutiny, IOM ConcludesScience, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Predictive and prognostic factors for non-small cell lung cancer--potholes in the road to the promised land.JNCI Journal of the National Cancer Institute, 2011
- What Information Should Be Required to Support Clinical “Omics” Publications?Clinical Chemistry, 2011
- Lung Cancer Cell Lines as Tools for Biomedical Discovery and ResearchJNCI Journal of the National Cancer Institute, 2010
- Towards patient-based cancer therapeuticsNature Biotechnology, 2010
- Microarrays: retracing stepsNature Medicine, 2007
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006